0.05Open0.05Pre Close0 Volume115 Open Interest0.50Strike Price0.00Turnover295.15%IV27.30%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.2401Delta1.1208Gamma12.40Leverage Ratio-0.0052Theta0.0000Rho-2.98Eff Leverage0.0003Vega
Adaptimmune Therapeutics Stock Discussion
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
newsfile· 2 mins ago
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...
On September 23, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a Mutual Release and Resolution Agreement (the “Agreement”) with Genentech Inc and F. Hoffmann-La Roche Ltd, (together “Genentech”). The parties entered into the Agreement following notice of termination of their Collaboration and License Agreement dated September 3, 2021 (the “Collaboration Agreement”) on April 8,...
so the spike in cash is from financing, fyi
after the product is approved, profitable, it's your time to shine.
$Adaptimmune Therapeutics (ADAP.US)$
come on
No comment yet